SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 81 filers reported holding SYROS PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $566,000 | +76.9% | 75,730 | +157.1% | 0.00% | +50.0% |
| Q4 2020 | $320,000 | +199.1% | 29,457 | +143.3% | 0.00% | +100.0% |
| Q3 2020 | $107,000 | +57.4% | 12,105 | +5.2% | 0.00% | -50.0% |
| Q1 2020 | $68,000 | -78.1% | 11,512 | -74.4% | 0.00% | 0.0% |
| Q4 2019 | $311,000 | – | 44,999 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures Fund IV General Partner LLC | 4,806,656 | $87,241,000 | 14.92% |
| Aisling Capital LLC | 908,565 | $16,490,000 | 3.89% |
| Foresite Capital Management III, LLC | 150,000 | $2,723,000 | 1.87% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,095,220 | $38,028,000 | 1.50% |
| Redmile Group, LLC | 946,182 | $15,058,000 | 1.44% |
| Casdin Capital, LLC | 50,000 | $908,000 | 0.90% |
| Eventide Asset Management | 150,000 | $2,723,000 | 0.17% |
| Weiss Multi-Strategy Advisers LLC | 45,857 | $832,000 | 0.06% |
| Baker Brothers Advisors | 204,465 | $3,711,000 | 0.04% |
| Alyeska Investment Group, L.P. | 70,000 | $1,271,000 | 0.01% |